Beta-lactamase CTX-M · SINGLE PROTEIN · Escherichia coli
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Beta-lactamase CTX-M shows approved-linked disease relevance led by infection. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9EXV5. Start with infection, then reuse UniProt Q9EXV5 as the stable protein anchor across project notes and exports.
Start with infection, then reuse UniProt Q9EXV5 as the stable protein anchor across project notes and exports.
Beta-lactamase CTX-M shows approved-linked disease relevance led by infection. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with infection because it currently carries approved-linked support. Linked drugs include RELEBACTAM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyBeta-lactamase
Review this target as Beta-lactamase CTX-M, mapped to UniProt Q9EXV5. ChEMBL maps the protein component as Beta-lactamase. Sequence length is 291 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Beta-lactamase CTX-M as ChEMBL target CHEMBL6131, mapped to UniProt Q9EXV5. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Beta-lactamase CTX-M is the right protein anchor across sources, using UniProt Q9EXV5 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why infection is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Beta-lactamase CTX-M |
| Target Type | SINGLE PROTEIN |
| Organism | Escherichia coli |
| UniProt | Q9EXV5 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Beta-lactamase |
| UniProt Accession | Q9EXV5 |
| Component Type | Protein |
| Sequence Length | 291 aa |
Beta-lactamase
Review this target as Beta-lactamase CTX-M, mapped to UniProt Q9EXV5. ChEMBL maps the protein component as Beta-lactamase. Sequence length is 291 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Beta-lactamase CTX-M shows approved-linked disease relevance led by infection. 5 more disease programs remain visible in the same review block.
Start review with infection because it currently carries approved-linked support. Linked drugs include RELEBACTAM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 11 | 2 | 8.4 |